Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Presented compelling new preclinical data demonstrating anti-tumor activity for OP-3136, a novel KAT6 inhibitor, with enhanced activity of palazestrant combinations at EORTC-NCI-AACR Symposium on Mole ...
News Medical5d
Key kinase involved in cell division linked to abnormal blood vessel growth in genetic disorder
Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...
Business Wire12d
Feinstein Institutes Research Shows Cancer Drugs Could Help With Vascular Disease
A drug commonly used to treat breast cancer might be able to help people living with hereditary hemorrhagic telangiectasia ...
gadgets36020d
OxygenOS 15 Unveiled With New AI Features, Redesigned UI and Default Gemini Assistant
Circle to Search is coming to compatible phones with OxygenOS 15 The update also adds new boot animation, icons, and shelf card choices OxygenOS 15 introduces Gemini-powered AI Notes ...
The Financial Express20d
NCCN Guidelines recognises Novartis’ ribociclib as Category 1 preferred breast cancer adjuvant treatment
Recommendation comes after recent FDA approval and positive CHMP Opinion for ribociclib (Kisqali) to help reduce the risk of recurrence in EBC. (Image Credits: Pexels) The NCCN Clinical Practice ...
Medical Xpress22d
Discovery of new mechanism explains how ovarian cancer disables immune cells
Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack—blocking the energy supply T cells depend on. The work ...
Novartis27d
Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer
If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...